Hefei Future Pharmaceutical Development

Hefei Future Pharmaceutical Development is a China-based pharmaceutical research and development company focused on the discovery and development of both innovative drugs and high-end generic medications. Founded in 2002 and headquartered in Hefei, Anhui Province, the company specializes in small molecule drug discovery across several therapeutic areas, including metabolic diseases, cardiovascular health, and anti-infectives. Their pipeline includes candidates targeting hyperuricemia and gout, such as the URAT1 inhibitor F-101, which has reached mid-to-late-stage clinical development. The company provides a range of services from drug synthesis and formulation development to clinical trial management and regulatory affairs. Hefei Future Pharmaceutical is recognized for its contributions to the pharmaceutical industry in Anhui and its commitment to improving patient access to high-quality treatments.